Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection

Gastroenterology

Volumn 152, Issue 1, 2017, Pages 164-175.e4

  Kwo, Paul ^a   Gane, Edward J ^b   Peng, Cheng Yuan ^c   Pearlman, Brian ^d   Vierling, John M ^e   Serfaty, Lawrence ^f   Buti, Maria ^g   Shafran, Stephen ^h   Stryszak, Paul ⁱ   Lin, Li ⁱ   Gress, Jacqueline ⁱ   Black, Stuart ⁱ   Dutko, Frank J ⁱ   Robertson, Michael ⁱ   Wahl, Janice ⁱ   Lupinacci, Lisa ⁱ   Barr, Eliav ⁱ   Haber, Barbara ⁱ  

^a INDIANA UNIVERSITY   (United States)

^b Auckland Clinical Studies   (New Zealand)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d Department of Pathology Atlanta Veterans Affairs Medical Center   (Georgia)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f HÔPITAL SAINT ANTOINE   (France)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

C EDGE Treatment Experienced; Hepatitis C; Randomized; Therapy

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DOLUTEGRAVIR; ELBASVIR PLUS GRAZOPREVIR; EMTRICITABINE; HEMOGLOBIN; LAMIVUDINE PLUS RALTEGRAVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON; RIBAVIRIN; RILPIVIRINE; SIMEPREVIR; TENOFOVIR; VIRUS RNA; 2-(PYRROLIDIN-2-YL)-5-(2-(4-(5-(PYRROLIDIN-2-YL)-1H-IMIDAZOL-2-YL)PHENYL)BENZOFURAN-5-YL)-1H-IMIDAZOLE; ANTIVIRUS AGENT; BENZOFURAN DERIVATIVE; DRUG COMBINATION; IMIDAZOLE DERIVATIVE; MK-5172; QUINOXALINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGIONEUROTIC EDEMA; ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; ASCITES; ASIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CENTRAL AMERICA; CHRONIC HEPATITIS C; CHRONOPHARMACOLOGY; COLITIS; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIGESTIVE SYSTEM INFLAMMATION; DOSE RESPONSE; DRUG ABUSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG OVERDOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOMETRIUM POLYP; EUROPE; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C RAPID TEST; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HIP FRACTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIVER CIRRHOSIS; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NORTH AMERICA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REBOUND; RELAPSE; RIB FRACTURE; SIDE EFFECT; SUDDEN DEAFNESS; SUICIDAL IDEATION; TIBIA FRACTURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT INTERRUPTION; TREATMENT RESPONSE; UNCONSCIOUSNESS; UNSTABLE ANGINA PECTORIS; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; RETREATMENT; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; BENZOFURANS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; QUINOXALINES; RETREATMENT; RIBAVIRIN; RNA, VIRAL; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE; YOUNG ADULT;

EID: 85006324053     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.09.045     Document Type: Article

References (26)

1. 1 Harvoni [package insert]. Foster City, CA; Gilead Sciences, Inc.; 2016.
2. 2 Afdhal, N., Reddy, K.R., Nelson, D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370 (2014), 1483–1493.
3. 3 Pianko, S., Flamm, S.L., Shiffman, M.L., et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med 163 (2015), 809–817.
4. 4 EPCLUSA [package insert]. Foster City, CA; Gilead Sciences, Inc; 2016.
5. 5 Zepatier [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2016.
6. 6 Coburn, C.A., Meinke, P.T., Chang, W., et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem 8 (2013), 1930–1940.
7. 7 Summa, V., Ludmerer, S.W., McCauley, J.A., et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 56 (2012), 4161–4167.
8. 8 Harper, S., McCauley, J.A., Rudd, M.T., et al. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med Chem Lett 3 (2012), 332–336.
9. 9 Howe, A.Y., Black, S., Curry, S., et al. Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Clin Infect Dis 59 (2014), 1657–1665.
10. 10 Lahser F, Liu R, Bystol K, et al. A combination containing MK-5172 (HCV N53 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in HCV replicons. Presented at The Liver Meeting 2012, November 9–13, 2012, Boston, MA.
11. 11 Forns, X., Gordon, S.C., Zuckerman, E., et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 63 (2015), 564–572.
12. 12 Rockstroh, J.K., Nelson, M., Katlama, C., et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2 (2015), e319–e327.
13. 13 Lawitz, E., Gane, E., Pearlman, B., et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385 (2014), 1075–1086.
14. 14 Sulkowski, M., Hezode, C., Gerstoft, J., et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385 (2014), 1087–1097.
15. 15 Zeuzem, S., Ghalib, R., Reddy, K.R., et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163 (2015), 1–13.
16. 16 Roth, D., Nelson, D.R., Bruchfeld, A., et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386 (2015), 1537–1545.
17. 17 Leitner, T., Halapi, E., Scarlatti, G., et al. Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques 15 (1993), 120–127.
18. 18 Zeuzem, S., Berg, T., Gane, E., et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 146 (2014), 430–441.
19. 19 Miettinen, O., Nurminen, M., Comparative analysis of two rates. Stat Med 4 (1985), 213–226.
20. 20 Jacobson, I.M., Dore, G.J., Foster, G.R., et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384 (2014), 403–413.
21. 21 Manns, M., Marcellin, P., Poordad, F., et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 384 (2014), 414–426.
22. 22 Kwo, P., Gitlin, N., Nahass, R., A phase 3, randomized, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1 [abstract]. J Hepatol, 62, 2015, S270.
23. 23 Lawitz, E., Matusow, G., DeJesus, E., et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology 64 (2016), 360–369.
24. 24 Sarrazin, C., Dvory-Sobol, H., Svarovskaia, E.S., et al. The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- RBV [abstract]. J Hepatol, 62(Suppl 2), 2015, S260.
25. 25 AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
26. 26 Gane, E.J., Pianko, S., Roberts, S.K., et al. Phase 2, randomized, open-label clinical trials of the efficacy and safety of grazoprevir and MK-3682 (NS5B polymerase inhibitor) with either elbasvir or MK-8408 (NS5A inhibitor) in patients with chronic HCV GT1, 2 or 3 infection (part A of C-CREST-1 & 2) [abstract]. Hepatology, 62, 2015, 1389A.